Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 1Phase 3 1Phase 1/2 1

Status

Recruiting 4Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 3

Study Type

Interventional 6Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 7Lymphoid 7

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 54Lymphoma, Mantle-Cell 31Lymphoma, Large B-Cell, Diffuse 17Lymphoma, Non-Hodgkin 14Lymphoma 11Leukemia, B-Cell 7Lymphoma, Follicular 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma, B-Cell 5Leukemia 5Waldenstrom Macroglobulinemia 4Multiple Myeloma 3Recurrence 2Pancreatic Neoplasms 2Lymphoproliferative Disorders 2Lymphatic Diseases 2Leukemia, Prolymphocytic 2Hematologic Neoplasms 2Cardiovascular Diseases 2Squamous Cell Carcinoma of Head and Neck 1Pyloric Stenosis, Hypertrophic 1Part1: Advanced B-cell Malignancies 1Ovarian Neoplasms 1Neuritis 1Neoplasms 1Neoplasm, Residual 1Leukemia, Hairy Cell 1Immunoproliferative Disorders 1Immune System Diseases 1Hodgkin Disease 1

Interventions

Cyclophosphamide 18ofatumumab 14fludarabine 12Rituximab 11ibrutinib 10fludarabine phosphate 9acalabrutinib 7obinutuzumab 6Lenalidomide 6Bendamustine Hydrochloride 6venetoclax 5pirtobrutinib 4Vincristine 4Mesna 4Melphalan 4Immunotherapy, Adoptive 4Whole-Body Irradiation 3Mycophenolic Acid 3Chlorambucil 3Bortezomib 3Alemtuzumab 3spebrutinib 2navitoclax 2idelalisib 2Tacrolimus 2Tablets 2Stem Cell Transplantation 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2KW-2478 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Leukemia, B-Cell × acalabrutinib × Clear all
NCT05557695 2026-06-02

EPIC

AstraZeneca

Recruiting
350 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT06651970 2026-05-18

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

AstraZeneca

Phase 4 Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Heart Failure, Lymphatic Diseases, Leukemia, B-Cell

NCT06564038 2026-05-14

Soundtrack-E

AstraZeneca

Phase 1/2 Recruiting
408 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT04883749 2025-06-08

CLL-Frail

German CLL Study Group

Phase 2 Completed
53 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT03787264 2024-12-30

CLL2-BAAG

German CLL Study Group

Phase 2 Completed
46 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT03836261 2024-12-27

AMPLIFY

Acerta Pharma BV

Phase 3 Active not recruiting
984 enrolled 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03899337 2023-01-09

STELLAR

University of Birmingham

Phase 2 Recruiting
105 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡